Novo Nordisk Acquires Emisphere’s Eligen® Technology for US$1.8 B
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 11 (Table of Contents)
Published: 19 Nov-2020
DOI: 10.3833/pdr.v2020.i11.2570 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In its second largest M&A deal to date, Novo Nordisk has agreed to acquire Emisphere Technologies, a drug delivery company focused on the development of oral formulations of therapeutics using its Eligen® technology, for US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS